Navigation Links
Scott & White Healthcare and American Cancer Society enter into partnership for prevention study
Date:10/25/2011

TEMPLE, Texas (Tuesday, October 25, 2011) - Today, Scott & White Healthcare and the American Cancer Society have announced a joint collaboration for the Cancer Prevention Study 3 (CPS-3), the first study of its kind in more than 20 years. The American Cancer Society CPS-3 study is enrolling at least 300,000 adults from various racial/ethnic backgrounds from across the U.S., to better understand how to prevent the disease.

Scott & White Healthcare is the first, and to date only, health system to form such a partnership with the American Cancer Society (Society) High Plains Division which covers a six-state area (TX, OK, MO, NE, KS, and HI). Scott & White will host enrollment sites and recruit community members to join the study and the Society will follow these participants for 20-30 years. Enrollment sites will be at Scott & White hospitals in Temple, Waco, and Round Rock, and potentially other locations at a later date. The enrollment period will be from late March until early April 2012.

Men and women between the ages of 30 and 65 years who have no personal history of cancer are invited to join this historic research study. The first CPS study, conducted in the 1950s, discovered the link between cigarette smoking and lung cancer. The second such study which began in the 1980s and is still ongoing determined the link between obesity and the risk of cancer occurrence. CPS-3 will give researchers the ability to examine how not only lifestyle impacts cancer risk but genetic factors, hormonal factors and other markers in the blood that are also related to the development, or prevention, of cancer.

"This partnership is another milestone in our journey to becoming an NCI-designated cancer institute," said Andrejs E. Avots-Avotins, M.D., Ph.D., chairman of the Board of Directors at Scott & White Healthcare, and member of the Board of Directors of the Society's High Plains Division.

"There are millions of people who have avoided a diagnosis of cancer because of the results of our first two prevention studies. This new study will help us determine how behaviors and lifestyles might lead to cancer," said Mike Dany, CEO of the Society's High Plains Division. "Currently, there are no other studies of this magnitude in the U.S. that enable researchers to look at various racial and ethnic populations and cancer risk."

The Scott & White Cancer Institute, which includes the Vasicek Cancer Treatment Center in Temple, offers highly-specialized and coordinated care throughout the entire Scott & White system. Patients and families have one-stop access to cancer diagnosis and treatment, backed by medical research and education. The Cancer Research Institute (CRI), a non-profit arm of the Scott & White Cancer Institute, accelerates the development of new therapies for human diseases. Universities, investigators, foundations and companies bring their discoveries to the CRI to complete the steps for introducing new treatments to the clinic.

"Collaborating with The American Cancer Society is an important step forward for the Scott & White Cancer Institute, the people of Central Texas and the nation in our shared fight against cancer," said Subhakar Mutyala, M.D., director of the Scott & White Cancer Institute and chairman of the department of radiation oncology.


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related medicine news :

1. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
2. Scott & White Healthcare pathologist is co-investigator on breast cancer study
3. James Scott Farrin Supports Radiothon for Duke Children's Hospital
4. SUNZ Insurance Company Selects Scott Robertson as President
5. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
6. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
7. New Varicose Vein Treatment Center Opens in Prescott, Arizona
8. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
9. Scott & White Healthcare clinical trials target lymphoma, leukemia
10. Scott & White Healthcare physician to help develop global guidelines for Alzheimers
11. Scott Harter at Atrion International Receives EHS Gold Award From PPG Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 ... ... on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. ... eye-catching label design. Featuring one of the world’s most powerful antioxidants, molecular ...
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a ... Scooters . , Mobility Scooters give freedom to people who need help getting around. ... may be facing a long period of rehabilitation after an illness or accident. There ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is a ... lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO of ... create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... GA (PRWEB) , ... December ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... the 2017 Information Security Executive® (ISE®) Central Awards. , Awards include the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education ... Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on ... “We are honored to have Amy E. Herman present at this year’s conference, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016   Lexicon Pharmaceuticals, ... results today from a Phase 2 clinical study of ... Lexicon in collaboration with JDRF, the leading global organization ... of this Phase 2 clinical trial, which randomized a ... of a once-daily 400 mg dose of sotagliflozin compared ...
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... PORTLAND, Oregon and PUNE, India ... a new report by Allied Market Research, titled, "Global Cancer ... the global revenue of cancer biomarkers market is projected to ... at a CAGR of 13.3% from 2016 to 2022. Omic ... share in 2015 and is expected to maintain its dominance ...
Breaking Medicine Technology: